Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCENDE-SBRT: SBRT vs Brachytherapy Boost in Unfavourable Risk Localized Prostate Cancer
NCT06235697Phase 3Recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Apr 2024
- Primary completion
- Oct 2032
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) (2 arms), sponsored by Canadian Cancer Trials Group. Primary endpoint: Progression-Free Survival at 8.6 years. Started Apr 2024; status: recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06235697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06235697.